SmithKline Beecham Requip for Parkinson's study shows 24% improvement in motor functioning.
SMITHKLINE REQUIP FOR PARKINSON's IMPROVES MOTOR FUNCTION 24% compared to a 3% decline on placebo, according to results from one of three Phase III studies of ropinirole presented at the American Academy of Neurology meeting in San Francisco March 26. The 24% improvement was statistically significant compared to placebo-treated patients with Parkinson's disease who had no or little exposure to dopaminergic anti-Parkinson therapy.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth